Systematic meta-analysis revealing a potential for targeted and personalized cancer therapeutics

The use of many anticancer drugs is problematic due to severe adverse effects. While the recent clinical launch of several kinase inhibitors led to tremendous progress, these targeted agents tend to be of non-specific nature within the kinase target class. A future strategy will be the development of nanocarrier-based systems for the active delivery of kinase inhibitors using cancer specific surface receptors. The rationale of this approach will guide the future design of transport vehicles, which will dock to receptors on cancer cells via specific ligands and deliver anticancer compounds after receptor mediated internalization. In addition to this, the approach is expected to be most effective by matching the inhibitor profiles of the delivered kinase inhibitors to the observed kinase gene expression profiles. The presented data demonstrate a large untapped potential for personalized cancer therapy using high-end targeted nanopharmaceuticals.